Biopharma competitors

Zippia score 4.1

Biopharma main competitors are MakroCare, Forest Laboratories, and Cubist Pharmaceuticals.

Competitor Summary. See how Biopharma compares to its main competitors:

Otsuka Pharmaceuticals has the most employees (7,500).
Employees at MakroCare earn more than most of the competitors, with an average yearly salary of $99,734.
The oldest company is Santen, founded in 1890.

Work at Biopharma?

Share your experience

Biopharma vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
Biopharma	1896	4.1	-	-	$200,000	500
Emergo Therapeutics	2017	3.3	Durham, NC	1	$130,000	7
Kantar Health	2009	4.3	New York, NY	1	$13.0M	600
MakroCare	1996	4.0	Newark, NJ	1	$21.4M	420
Santen	1890	4.8	Emeryville, CA	1	$2.4B	3,805
Cyberonics	1987	4.6	Houston, TX	3	$291.6M	660
Forest Laboratories	1954	4.8	New York, NY	1	$3.6B	6,200
Prometheus	1995	4.7	San Diego, CA	1	$6.8M	325
Axio Research	1979	3.8	Seattle, WA	1	$5.4M	50
SmithKline Beecham Holdings Corporation	1996	4.3	Wilmington, DE	1	-	1,500
Otsuka Pharmaceuticals	1989	4.9	Rockville, MD	3	$4.4B	7,500
Cubist Pharmaceuticals	1992	4.8	Lexington, MA	1	$926.4M	873
Lundbeck	2000	4.9	Deerfield, IL	1	$130.0M	750
Enzon Pharmaceuticals	1981	3.9	Cranford, NJ	1	$26,000	1

Rate how well Biopharma differentiates itself from its competitors.

Biopharma salaries vs competitors

Among Biopharma competitors, employees at MakroCare earn the most with an average yearly salary of $99,734.

Compare Biopharma salaries vs competitors

Company	Average salary	Hourly salary	Salary score
Biopharma	$69,292	$33.31	-
Emergo Therapeutics	$65,016	$31.26	-
Kantar Health	$81,519	$39.19	-
MakroCare	$99,734	$47.95	-
Santen	$75,896	$36.49	-
Cyberonics	$86,285	$41.48	-

Compare Biopharma job title salaries vs competitors

Company	Highest salary	Hourly salary
Biopharma	$90,094	$43.31
Cubist Pharmaceuticals	$104,137	$50.07
Axio Research	$95,794	$46.06
Forest Laboratories	$95,533	$45.93
SmithKline Beecham Holdings Corporation	$94,564	$45.46
Cyberonics	$94,154	$45.27
MakroCare	$93,273	$44.84
Otsuka Pharmaceuticals	$91,960	$44.21
Enzon Pharmaceuticals	$89,475	$43.02
Prometheus	$89,320	$42.94
Santen	$89,182	$42.88
Kantar Health	$89,163	$42.87
Emergo Therapeutics	$89,162	$42.87
Lundbeck	$88,647	$42.62

Do you work at Biopharma?

Does Biopharma effectively differentiate itself from competitors?

Biopharma jobs

Biopharma demographics vs competitors

Compare gender at Biopharma vs competitors

Job title	Male	Female
Kantar Health	41%	59%
Cubist Pharmaceuticals	52%	48%
Enzon Pharmaceuticals	53%	47%
Lundbeck	57%	43%
Prometheus	62%	38%
Biopharma	-	-

Male

Female

100%

75%

50%

25%

Biopharma

Prometheus

Lundbeck

Enzon Pharmaceuticals

Cubist Pharmaceuticals

Kantar Health

25%

50%

75%

100%

Compare race at Biopharma vs competitors

Company	White	Hispanic or Latino	Black or African American	Asian	Unknown	Diversity score
Cubist Pharmaceuticals	60%	12%	8%	17%	4%	9.9
Lundbeck	54%	15%	11%	14%	5%	9.7
Enzon Pharmaceuticals	52%	13%	10%	23%	3%	9.2
Prometheus	57%	19%	10%	10%	5%	9.8
Kantar Health	55%	18%	9%	15%	3%	9.6

Biopharma and similar companies CEOs

CEOBio

Michael Bonney

Cubist Pharmaceuticals

Deborah Dunsire

Lundbeck

Dr. William Carson H.

Otsuka Pharmaceuticals

Dr. William Carson H. is a President and Chief Executive Officer at Otsuka America Pharmaceutical, Inc. and is based in United States.

Richard L. Feinstein

Enzon Pharmaceuticals

Richard L Feinstein is a VP:Finance/CFO at ENZON PHARMACEUTICALS, INC.; Chief Financial Officer at USA Fitness Corps; and Board Member at USA Fitness Corps and is based in Greater New York City Area. He has worked as VP:Finance/Principal Financial Ofcr at ENZON PHARMACEUTICALS, INC.; Partner at KPMG; and CFO/Consultant at ImageProtect. Richard works or has worked as MEMBER at Association For A Better New York. He studied at Pace University.

Mark C. McKenna

Prometheus

Mr. McKenna serves as President, CEO and member of the board of Prometheus Biosciences. Prior to joining Prometheus Biosciences, Mr. McKenna was President & CEO of Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies. He joined Salix in March 2016 as the Senior Vice President and General Manager, responsible for the company’s gastrointestinal franchise. During his tenure, Mr. McKenna successfully led the company through a series of key strategic acquisitions, the launch of a number of new products, and delivered strong operating performance, with revenue increasing from $1.2B to $2B. Prior to joining Salix, Mr. McKenna spent more than a decade with Bausch + Lomb, most recently as Senior Vice President/General Manager of its U.S. Vision Care business. Prior to Bausch + Lomb, Mark held several roles of increasing responsibility at Johnson & Johnson. Mark holds a B.S. in Marketing from Arizona State University, an MBA from Azusa Pacific University and is a Fellow with the University of Pennsylvania, Wharton School of Business.

Dr. Fumihiro Sasa

Santen

Moise Khayrallah

Emergo Therapeutics

Moise Khayrallah is a Co-Founder, President & CEO at Addrenex Pharmaceuticals Inc; Board Member at North Carolina Biotechnology Center; and Chairman & Board of Directors at Valanbio Therapeutics and is based in Morrisville, North Carolina. He has worked as Entrepreneur In Residence at Blackstone Entrepreneurs Network; President, CEO and Co-Founder at Neuronex Inc; and Board Chair at Target RWE Health Evidence Solutions. Moise studied at University of North Carolina at Chapel Hill until 1993 and American University of Beirut between 1978 and 1981.

Lee Hooks

Axio Research

Lynnette Cooke

Kantar Health